In another active week for the IPO market, eight companies completed offerings, with the largest and most anticipated IPO, Wish (WISH), putting on an underwhelming performance. Surprisingly, this came alongside the best performing IPO of 2020...read more
BioAtla, a Phase 2 biotech developing selective antibody therapies for solid tumors, raised $189 million by offering 10.5 million shares at $18, above the range of $15 to $17. The company offered 1.1 million more shares than anticipated. At pricing, BioAtla...read more
Updated Monday, 12/14. Six IPOs and five SPACs are scheduled to raise $2.8 billion in the week ahead as the IPO market starts to slow down before the holidays. Bargain e-commerce platform Wish (WISH) plans to raise $1.1...read more
BioAtla, a Phase 2 biotech developing antibody therapies for solid tumor cancers, announced terms for its IPO on Wednesday. The San Diego, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17. At the...read more
US IPO Weekly Recap: WISH not granted in week of otherwise stellar returns
In another active week for the IPO market, eight companies completed offerings, with the largest and most anticipated IPO, Wish (WISH), putting on an underwhelming performance. Surprisingly, this came alongside the best performing IPO of 2020...read more
Solid tumor biotech BioAtla prices upsized IPO above the range at $18
BioAtla, a Phase 2 biotech developing selective antibody therapies for solid tumors, raised $189 million by offering 10.5 million shares at $18, above the range of $15 to $17. The company offered 1.1 million more shares than anticipated. At pricing, BioAtla...read more
US IPO Week Ahead: The IPO market makes a holiday WISH in a 6 IPO week
Updated Monday, 12/14. Six IPOs and five SPACs are scheduled to raise $2.8 billion in the week ahead as the IPO market starts to slow down before the holidays. Bargain e-commerce platform Wish (WISH) plans to raise $1.1...read more
Solid tumor biotech BioAtla sets terms for $150 million IPO
BioAtla, a Phase 2 biotech developing antibody therapies for solid tumor cancers, announced terms for its IPO on Wednesday. The San Diego, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17. At the...read more